Farallon Capital Management
Latest statistics and disclosures from Farallon Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, RVMD, EA, BBIO, PTGX, and represent 47.15% of Farallon Capital Management's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$4.5B), IMVT (+$164M), ROIV (+$164M), BSX (+$130M), BBIO (+$103M), TNGX (+$99M), EA (+$92M), NVO (+$88M), BIDU (+$87M), TMO (+$84M).
- Started 22 new stock positions in SGMT, Jatt Ii Acquisition Corp, BC, SOXX, AXTA, Parabilis Medicines, IDXX, TSHA, Microstrategy, CMC. WAY, SMG, WRBY, Strategy Inc Note 3/0, Mobia Med, SPY, IFRX, NVS, BIIB, Kailera Therapeutics, GNTX, Alamar Biosciences.
- Reduced shares in these 10 stocks: , Invesco Exchange Traded Fd T put (-$691M), MSFT (-$460M), AMZN (-$378M), AON (-$375M), SCHW (-$372M), GOOG (-$286M), NTRA (-$269M), , AVGO (-$237M).
- Sold out of its positions in AIR, ADPT, AFRM, GOOG, ALT, ALMS, COR, FOLD, AMKR, Apellis Pharmaceuticals.
- Farallon Capital Management was a net seller of stock by $-837M.
- Farallon Capital Management has $22B in assets under management (AUM), dropping by 13.69%.
- Central Index Key (CIK): 0000909661
Tip: Access up to 7 years of quarterly data
Positions held by Farallon Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Farallon Capital Management
Farallon Capital Management holds 89 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY) | 20.7 | $4.5B | NEW | 6.0M | 746.77 |
|
| Revolution Medicines (RVMD) | 11.7 | $2.5B | 14M | 187.28 |
|
|
| Electronic Arts (EA) | 7.5 | $1.6B | +6% | 7.9M | 205.04 |
|
| Bridgebio Pharma (BBIO) | 3.7 | $800M | +14% | 11M | 74.48 |
|
| Protagonist Therapeutics (PTGX) | 3.6 | $778M | 6.3M | 122.58 |
|
|
| Exelixis (EXEL) | 3.4 | $733M | +2% | 14M | 54.41 |
|
| Liquidia Corporation Com New (LQDA) | 3.1 | $667M | -3% | 8.4M | 79.73 |
|
| Amazon (AMZN) | 2.9 | $628M | -37% | 2.6M | 238.34 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.9 | $619M | 5.6M | 110.94 |
|
|
| Natera (NTRA) | 2.8 | $602M | -30% | 2.2M | 271.45 |
|
| UnitedHealth (UNH) | 2.4 | $528M | -30% | 1.3M | 415.63 |
|
| Thermo Fisher Scientific (TMO) | 2.4 | $526M | +19% | 1.0M | 501.36 |
|
| Roivant Sciences SHS (ROIV) | 2.3 | $506M | +47% | 14M | 35.39 |
|
| Aon Shs Cl A (AON) | 2.1 | $459M | -44% | 1.4M | 331.69 |
|
| Boston Scientific Corporation (BSX) | 2.1 | $449M | +40% | 11M | 42.68 |
|
| Broadcom (AVGO) | 2.0 | $435M | -35% | 1.2M | 377.75 |
|
| Microsoft Corporation (MSFT) | 1.9 | $415M | -52% | 1.1M | 373.02 |
|
| Tango Therapeutics (TNGX) | 1.8 | $384M | +34% | 12M | 31.26 |
|
| Kkr & Co (KKR) | 1.7 | $378M | -11% | 4.1M | 91.78 |
|
| Synopsys (SNPS) | 1.7 | $370M | -31% | 830k | 446.07 |
|
| Beam Therapeutics (BEAM) | 1.6 | $351M | 10M | 34.32 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 1.6 | $336M | +7% | 9.0M | 37.42 |
|
| Grail (GRAL) | 1.3 | $284M | +27% | 4.2M | 68.27 |
|
| Wabtec Corporation (WAB) | 1.1 | $241M | -44% | 895k | 269.60 |
|
| Immunovant (IMVT) | 1.0 | $224M | +275% | 5.8M | 38.53 |
|
| Twist Bioscience Corp (TWST) | 1.0 | $220M | +49% | 2.1M | 102.88 |
|
| Agios Pharmaceuticals (AGIO) | 1.0 | $220M | +4% | 5.9M | 37.11 |
|
| Aramark Hldgs (ARMK) | 1.0 | $206M | -40% | 3.6M | 56.90 |
|
| Baidu Spon Adr Rep A (BIDU) | 0.6 | $138M | +171% | 1.2M | 114.29 |
|
| Novo-nordisk A S Adr (NVO) | 0.6 | $126M | +234% | 2.6M | 47.94 |
|
| Acadia Healthcare (ACHC) | 0.6 | $125M | +143% | 4.2M | 29.53 |
|
| Brightspring Health Svcs (BTSG) | 0.6 | $121M | +7% | 1.7M | 69.74 |
|
| Astrazeneca Ord (AZN) | 0.5 | $109M | +153% | 574k | 189.62 |
|
| Johnson & Johnson (JNJ) | 0.5 | $104M | +175% | 408k | 253.97 |
|
| Ishares Tr Ishares Semicdtr Put Option (SOXX) | 0.4 | $83M | NEW | 130k | 640.76 |
|
| Strategy Note 12/0 (Principal) | 0.3 | $75M | +122% | 88M | 0.86 |
|
| Parabilis Medicines | 0.3 | $65M | NEW | 2.4M | 27.37 |
|
| Novartis Sponsored Adr (NVS) | 0.3 | $57M | NEW | 363k | 156.72 |
|
| Guardant Health (GH) | 0.2 | $48M | +3927% | 322k | 150.03 |
|
| Vnet Group Note 2.000%10/0 (Principal) | 0.2 | $47M | 45M | 1.04 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $46M | +172% | 2.5M | 18.48 |
|
| Joyy Ads Repstg Com A (JOYY) | 0.2 | $46M | +20% | 699k | 65.99 |
|
| Assembly Biosciences Com New (ASMB) | 0.2 | $44M | +30% | 1.6M | 27.48 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $35M | -15% | 2.4M | 14.58 |
|
| Maze Therapeatics (MAZE) | 0.2 | $33M | +197% | 1.1M | 29.84 |
|
| Cg Oncology Call Option (CGON) | 0.1 | $28M | -40% | 400k | 71.05 |
|
| Merck & Co (MRK) | 0.1 | $26M | -44% | 199k | 128.50 |
|
| Warby Parker Cl A Com (WRBY) | 0.1 | $25M | NEW | 828k | 30.34 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.1 | $25M | 2.3M | 10.88 |
|
|
| Kailera Therapeutics Common Stock | 0.1 | $24M | NEW | 1.1M | 22.03 |
|
| Rio Tinto Sponsored Adr (RIO) | 0.1 | $17M | +241% | 184k | 94.93 |
|
| Axalta Coating Sys (AXTA) | 0.1 | $16M | NEW | 478k | 34.22 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.1 | $16M | +6000% | 122k | 133.26 |
|
| Vnet Group Sponsored Ads A (VNET) | 0.1 | $16M | +219% | 2.0M | 8.04 |
|
| Netease Sponsored Ads (NTES) | 0.1 | $16M | -57% | 124k | 128.14 |
|
| Biogen Idec (BIIB) | 0.1 | $15M | NEW | 71k | 216.06 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $15M | NEW | 2.3M | 6.81 |
|
| Mobia Med Common Stock | 0.1 | $15M | NEW | 1.1M | 13.40 |
|
| Strategy Note 2.250% 6/1 (Principal) | 0.1 | $14M | NEW | 15M | 0.95 |
|
| Minerva Neurosciences Com New (NERV) | 0.1 | $13M | 2.4M | 5.55 |
|
|
| Alamar Biosciences Common Stock | 0.1 | $13M | NEW | 463k | 27.09 |
|
| Alvotech Ordinary Shares (ALVO) | 0.0 | $11M | +1332% | 2.9M | 3.69 |
|
| Beta Bionics (BBNX) | 0.0 | $9.3M | -83% | 595k | 15.67 |
|
| Inflarx Nv (IFRX) | 0.0 | $7.4M | NEW | 3.3M | 2.24 |
|
| Scotts Miracle-gro Cl A (SMG) | 0.0 | $6.0M | NEW | 88k | 68.11 |
|
| Waystar Holding Corp (WAY) | 0.0 | $5.4M | NEW | 265k | 20.53 |
|
| Brunswick Corporation (BC) | 0.0 | $5.1M | NEW | 61k | 84.24 |
|
| Gentex Corporation (GNTX) | 0.0 | $5.0M | NEW | 199k | 25.27 |
|
| IDEXX Laboratories (IDXX) | 0.0 | $4.7M | NEW | 9.0k | 526.44 |
|
| Prime Medicine (PRME) | 0.0 | $4.6M | 1.2M | 3.69 |
|
|
| Commercial Metals Company (CMC) | 0.0 | $4.2M | NEW | 67k | 62.75 |
|
| Jatt Ii Acquisition Corp Ord Shs | 0.0 | $3.4M | NEW | 300k | 11.36 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.0 | $3.2M | NEW | 415k | 7.73 |
|
| Strategy Note 3/0 (Principal) | 0.0 | $2.3M | NEW | 2.6M | 0.88 |
|
| Summit Midstream Corporation (SMC) | 0.0 | $1.7M | 58k | 28.48 |
|
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.0 | $1.4M | -88% | 40k | 33.88 |
|
| Revolution Medicines *w Exp 12/17/202 (RVMDW) | 0.0 | $1.1M | 120k | 9.40 |
|
|
| Cogent Biosciences (COGT) | 0.0 | $658k | 17k | 38.70 |
|
|
| Aleanna *w Exp 12/13/202 (ANNAW) | 0.0 | $297k | 990k | 0.30 |
|
|
| Aleanna Com Cl A (ANNA) | 0.0 | $227k | 78k | 2.90 |
|
|
| Welltower Inc Com reit (WELL) | 0.0 | $227k | -99% | 1.0k | 226.97 |
|
| Solid Power *w Exp 12/08/202 (SLDPW) | 0.0 | $41k | 405k | 0.10 |
|
|
| Blue Gold *w Exp 04/01/203 (BGLWW) | 0.0 | $31k | -14% | 256k | 0.12 |
|
| Pacific Biosciences of California (PACB) | 0.0 | $24k | -89% | 14k | 1.68 |
|
| Geron Corporation (GERN) | 0.0 | $18k | -66% | 14k | 1.28 |
|
| Nvni Group *w Exp 11/01/202 (NVNIW) | 0.0 | $18k | 375k | 0.05 |
|
|
| Canopy Growth Corporation Com New (CGC) | 0.0 | $17k | -40% | 18k | 0.95 |
|
| Rani Therapeutics Hldgs Com Cl A (RANI) | 0.0 | $16k | -73% | 21k | 0.76 |
|
| Beyond Meat (BYND) | 0.0 | $14k | 19k | 0.75 |
|
Past Filings by Farallon Capital Management
SEC 13F filings are viewable for Farallon Capital Management going back to 2010
- Farallon Capital Management 2026 Q2 filed Aug. 14, 2026
- Farallon Capital Management 2025 Q4 amended filed Aug. 14, 2026
- Farallon Capital Management 2026 Q1 amended filed Aug. 14, 2026
- Farallon Capital Management 2026 Q1 filed May 15, 2026
- Farallon Capital Management 2025 Q4 amended filed May 15, 2026
- Farallon Capital Management 2024 Q4 amended filed Feb. 17, 2026
- Farallon Capital Management 2025 Q1 amended filed Feb. 17, 2026
- Farallon Capital Management 2025 Q2 amended filed Feb. 17, 2026
- Farallon Capital Management 2025 Q3 restated filed Feb. 17, 2026
- Farallon Capital Management 2025 Q4 filed Feb. 17, 2026
- Farallon Capital Management 2023 Q3 amended filed Nov. 14, 2025
- Farallon Capital Management 2023 Q4 amended filed Nov. 14, 2025
- Farallon Capital Management 2024 Q1 amended filed Nov. 14, 2025
- Farallon Capital Management 2024 Q2 amended filed Nov. 14, 2025
- Farallon Capital Management 2024 Q3 amended filed Nov. 14, 2025
- Farallon Capital Management 2024 Q4 amended filed Nov. 14, 2025